Nicholson most recently served as chief executive officer of Nimbus Therapeutics.
Prior to Nimbus, Nicholson spent 25 years at Merck, where he held various strategic, leadership and operational roles across diverse therapeutic areas including inflammation, immunology and neuroscience, amongst others.
Nicholson began his career at Merck Frosst in Montreal as a senior research biologist and advanced through various positions of increasing responsibility, including vice president and site head of the Merck Neurosciences Research site in San Diego, vice president of immunology and infectious diseases and then vice president and worldwide discovery head for the Bone, Respiratory, Immunology and Endocrine franchise based in New Jersey.
Nicholson has co-authored more than 150 publications in peer-reviewed scientific and medical journals and is internationally recognized for his contributions to the field of apoptotic cell death.
He is the recipient of multiple academic and professional honors. Don is also a member of the board of directors of Kymera Therapeutics and Generation Bio.
Jnana Therapeutics is a biotechnology company creating the first drug discovery platform to unlock the solute carrier family of metabolite transporters as a therapeutic target class.
Jnana is systematically targeting SLCs, the cell's metabolite gates, to advance first-in-class therapies for diseases where patients have limited or no treatment options.
Headquartered in Boston, Jnana launched in 2017 with USD 50m in series A financing from investors including Polaris Partners, Avalon Ventures, Versant Ventures, AbbVie Ventures and Pfizer R and D Innovate.
Poolbeg PHarma plc receives notice of allowance for POLB 001 patent
RedHill Biopharma secures USPTO Patent for Talicia, extending protection through 2034
Micron Biomedical names new scientific advisor to CEO
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial